Publication | Open Access

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer

Gastrointestinal OncologyMedicineColorectal CancerPharmacotherapyThree-weekly ScheduleCancer TreatmentOncologyRadiation OncologyRadiologyHealth Sciences